Zoetis Inc. (NYSE:ZTS) Position Increased by Alliance Wealth Advisors LLC UT

Alliance Wealth Advisors LLC UT increased its position in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 23.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 19,720 shares of the company's stock after purchasing an additional 3,700 shares during the period. Alliance Wealth Advisors LLC UT's holdings in Zoetis were worth $3,213,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also added to or reduced their stakes in the company. Mizuho Securities USA LLC increased its holdings in Zoetis by 13,726.9% during the 3rd quarter. Mizuho Securities USA LLC now owns 4,865,000 shares of the company's stock worth $950,524,000 after purchasing an additional 4,829,815 shares in the last quarter. International Assets Investment Management LLC increased its holdings in Zoetis by 41,235.7% during the 3rd quarter. International Assets Investment Management LLC now owns 939,974 shares of the company's stock worth $183,652,000 after purchasing an additional 937,700 shares in the last quarter. Assenagon Asset Management S.A. increased its holdings in Zoetis by 296.9% during the 4th quarter. Assenagon Asset Management S.A. now owns 889,444 shares of the company's stock worth $144,917,000 after purchasing an additional 665,331 shares in the last quarter. Nordea Investment Management AB increased its holdings in Zoetis by 38.3% during the 4th quarter. Nordea Investment Management AB now owns 2,065,514 shares of the company's stock worth $336,266,000 after purchasing an additional 572,511 shares in the last quarter. Finally, Holocene Advisors LP bought a new stake in Zoetis during the 3rd quarter worth approximately $110,809,000. 92.80% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities research analysts have issued reports on ZTS shares. Leerink Partnrs upgraded Zoetis to a "strong-buy" rating in a research report on Monday, December 2nd. Leerink Partners started coverage on Zoetis in a research report on Monday, December 2nd. They set an "outperform" rating and a $215.00 target price on the stock. JPMorgan Chase & Co. increased their target price on Zoetis from $225.00 to $230.00 and gave the stock an "overweight" rating in a research report on Friday, October 11th. UBS Group initiated coverage on Zoetis in a research report on Monday, December 9th. They set a "neutral" rating and a $196.00 target price on the stock. Finally, Stifel Nicolaus lowered their price objective on Zoetis from $210.00 to $180.00 and set a "buy" rating on the stock in a research report on Tuesday, January 7th. One equities research analyst has rated the stock with a hold rating, ten have assigned a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, Zoetis currently has a consensus rating of "Buy" and an average price target of $215.00.

Zoetis Trading Up 0.2 %

Shares of NYSE ZTS traded up $0.30 during midday trading on Tuesday, reaching $172.24. 2,696,175 shares of the stock were exchanged, compared to its average volume of 2,685,644. Zoetis Inc. has a 52-week low of $144.80 and a 52-week high of $200.53. The stock has a 50 day moving average price of $169.48 and a 200-day moving average price of $179.39. The company has a market capitalization of $77.71 billion, a P/E ratio of 32.38, a P/E/G ratio of 2.72 and a beta of 0.90. The company has a current ratio of 3.69, a quick ratio of 2.27 and a debt-to-equity ratio of 1.26.

Zoetis (NYSE:ZTS - Get Free Report) last announced its quarterly earnings results on Monday, November 4th. The company reported $1.58 earnings per share for the quarter, beating analysts' consensus estimates of $1.46 by $0.12. Zoetis had a net margin of 26.55% and a return on equity of 51.98%. The firm had revenue of $2.40 billion for the quarter, compared to analysts' expectations of $2.29 billion. During the same period in the previous year, the company posted $1.36 earnings per share. Zoetis's revenue was up 11.6% compared to the same quarter last year. Equities research analysts expect that Zoetis Inc. will post 5.9 earnings per share for the current fiscal year.

Zoetis Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, January 21st will be paid a $0.50 dividend. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.16%. The ex-dividend date is Tuesday, January 21st. This is a positive change from Zoetis's previous quarterly dividend of $0.43. Zoetis's payout ratio is 37.59%.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.